This biopharmaceutical company develops, manufactures, and markets both branded and generic prescription pharmaceuticals. They serve patients globally across regions like the EU and North America. Their product portfolio includes a range of dosage forms and focuses on key therapy areas such as endocrinology (as evidenced by their Cortrophin product). They prioritize quality assurance with GMP certifications and possess patents for some of their products, demonstrating innovation within their field.
Manufacturer usually replies in 7 days
Nimodipine is a medication used to prevent migraines and treat ischemic stroke, and subarachnoid hemorrhage. Manufacturers of nimodipine produce it both as a standalone medication, in combination with citicoline. Nimodipine suppliers market it in the form of oral capsules, oral solutions, and intravenous liquids.
The developer and earliest manufacturer of nimodipine is Bayer, who first introduced it into the pharmaceutical market in 1985 under the trade name Nimotop. Currently, the drug is approved in over 60 countries. Other major suppliers of nimodipine globally include Sun Pharmaceuticals, Heritage Pharmaceuticals, Bionpharma, Arbor, Thepharmanetwork, and Sofgen.
Nimodipine suppliers and distributors market both generic and trade name formulations of the drug. Buyers are advised that online sellers may attempt to market fraudulent versions of the drug, whereas Pipeline Pharma, through its pre-auditing and quality control procedures ensures that only verified nimodipine manufacturers and wholesalers enter our online marketplace, offering you a risk-free B2B pharmaceutical sales platform.
The retail price per 100 (30mg) capsules of trade name nimodipine is approximately 130,00 EUR, whereas the equivalent amount of generic nimodipine tablets costs around 50,00 EUR to 60,00 EUR. A single vial of trade name 10mg/50ml nimodipine injectable solution costs around 20,00 EUR.